Charles River Laboratories International, Inc.
CRLNYSEHealthcare● Active
$185.16
+$3.82(+2.11%)
Market Cap$8.9B
P/E Ratio—
52W High$228.88
52W Low$140.78
Charles River Laboratories International, Inc.（CRL）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · CRL · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Cost of Revenue | $2.79B | $2.72B | $2.63B | $2.51B | $2.21B |
| Gross Profit | $1.23B | $1.33B | $1.50B | $1.46B | $1.33B |
| Gross Margin %(computed) | 30.52% | 32.88% | 36.39% | 36.79% | 37.70% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.72B | $1.10B | $0.89B | $0.81B | $0.74B |
| Operating Income | $0.51B | $0.23B | $0.62B | $0.65B | $0.59B |
| Operating Margin %(computed) | 12.65% | 5.61% | 14.95% | 16.37% | 16.66% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.11B | $0.13B | $0.14B | $0.06B | $0.07B |
| Income Before Tax | ($0.10B) | $0.09B | $0.58B | $0.62B | $0.48B |
| Income Tax Expense | $0.04B | $0.07B | $0.10B | $0.13B | $0.08B |
| Net Income | ($0.14B) | $0.01B | $0.47B | $0.49B | $0.39B |
| Net Margin %(computed) | -3.59% | 0.25% | 11.49% | 12.23% | 11.04% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.91B | $0.58B | $1.03B | $0.99B | $0.82B |
| EBITDA Margin %(computed) | 22.69% | 14.35% | 24.99% | 24.80% | 23.17% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Charles River Laboratories International, Inc.
关于Charles River Laboratories International, Inc.（CRL）损益表
Charles River Laboratories International, Inc.（CRL）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，CRL实现营收$4.02B，毛利润$1.23B（毛利率30.52%），净利润($0.14B)（净利率-3.59%）。
常见问题
CRL · 4 问Charles River Laboratories International, Inc.（CRL）2025财年营收为$4.02B，同比down0.9%。
CRL revenueCRL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08